GRIN2A无义变异显著增加早发性精神分裂症等精神障碍风险并或可实现精准治疗
该研究在235名GRIN2A致病性变异携带者中调查精神症状,发现GRIN2A无义变异与精神分裂症等广谱精神障碍显著相关,且多在儿童或青少年期起病。4名GRIN2A无义变异相关精神障碍患者接受L-丝氨酸后神经精神表型均改善。
要点
- GRIN2A无义变异显著增加早发性精神分裂症等精神障碍风险。
- GRIN2A无义变异相关精神障碍可在儿童或青少年期起病。
- L-丝氨酸或可改善GRIN2A无义变异相关神经精神表型。
核心结论
- GRIN2A无义变异与精神分裂症等广谱精神障碍显著相关,是早发性甚至孤立性精神障碍的首个单基因病因。
- GRIN2A相关精神障碍可在儿童或青少年期起病,部分以孤立性精神障碍形式出现。
- L-丝氨酸对GRIN2A无义变异相关精神障碍患者的神经精神表型有改善作用。
研究设计与样本
- 研究纳入235名携带GRIN2A致病性变异的个体,这些个体此前已入组全球GRIN登记库。
- 研究比较GRIN2A无义变异与错义变异及纵向人群队列(FinRegistry)的精神障碍关联。
- 研究对4名GRIN2A无义变异相关精神障碍患者应用L-丝氨酸进行观察。
主要发现
- GRIN2A无义变异与包括精神分裂症在内的广谱精神障碍显著相关。
- GRIN2A无义变异相关精神障碍在儿童或青少年期起病,早于一般人群平均成人起病年龄。
- 在68%的癫痫与精神障碍共病个体中,精神障碍在癫痫终止后起病,且癫痫终止年龄与精神障碍起病相关。
- GRIN2A无义变异相关表型偶可以孤立性精神障碍形式出现,即精神分裂症或心境障碍不伴智力障碍和/或癫痫等GRIN2A特异性症状。
- 4名接受L-丝氨酸的GRIN2A无义变异相关精神障碍患者均出现神经精神表型改善。
关键数值与推荐
- 研究涉及235名GRIN2A致病性变异携带者。
- 68%的癫痫与精神障碍共病个体中精神障碍在癫痫终止后起病。
- 4名GRIN2A无义变异相关精神障碍患者接受L-丝氨酸后神经精神表型改善。
临床怎么用
- 对GRIN2A无义变异相关精神障碍患者应考虑基因检测以改善诊断。
- 增加NMDAR共激动剂脑浓度可能是针对GRIN2A无义变异所致谷氨酸能信号缺陷的精准治疗方向。
局限性
- L-丝氨酸应用仅涉及4名个体,样本量小。
- 研究为观察性登记库分析,因果推断受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rare genetic factors have been shown to substantially contribute to mental illness, but so far, no precision treatments for mental disorders have been described. It was recently identified that rare variants in GRIN2A encoding the GluN2A subunit of the N-methyl-D-aspartate receptor (NMDAR) confer a substantial risk for schizophrenia. To determine the prevalence of mental disorders among individuals with GRIN2A-related disorders, we enquired the presence of psychiatric symptoms in 235 individuals with pathogenic variants in GRIN2A who had previously enrolled in our global GRIN registry. We identified null variants in GRIN2A (GRIN2Anull) to be significantly associated with a broad spectrum of mental disorders including schizophrenia compared to a longitudinal population cohort (FinRegistry) as well as missense variants (GRIN2Amissense). In our cohort, GRIN2Anull-related mental disorders manifest in early childhood or adolescence, which is substantially earlier than the average adult onset in the general population. In 68% of co-incident epilepsy and mental disorder, mental disorders start after epilepsy offset and the age of epilepsy offset correlated with mental disorder onset. GRIN2Anull-related phenotypes appear to occasionally even manifest as isolated mental disorder, i.e. as schizophrenia or mood disorder without further GRIN2A-specific symptoms, such as intellectual disability and/or epilepsy. As L-serine is known to mediate co-agonistic effects on the NMDAR, we applied it to four individuals with GRIN2Anull-related mental disorders, all of whom experienced improvements of their neuropsychiatric phenotype. GRIN2Anull appears to be the first monogenic cause of early-onset and even isolated mental disorders, such as early-onset schizophrenia. Genetic testing should be considered in the diagnostic work-up of affected individuals to improve diagnosis and potentially offer personalized treatment as increasing brain concentrations of NMDAR co-agonists appears to be a promising precision treatment approach successfully targeting deficient glutamatergic signaling in individuals with mental disorders, i.e. due to GRIN2Anull.
引用
- Lemke JR, Eoli A, Krey I, et al. GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy. Mol Psychiatry. 2025. PMID: 41087560. doi:10.1038/s41380-025-03279-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。